173 related articles for article (PubMed ID: 36753993)
1. Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.
Pomej K; Balcar L; Shmanko K; Welland S; Himmelsbach V; Scheiner B; Mahyera A; Mozayani B; Trauner M; Finkelmeier F; Weinmann A; Vogel A; Pinter M
ESMO Open; 2023 Feb; 8(1):100783. PubMed ID: 36753993
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Jang YJ; Kim EJ; Kim HD; Kim KP; Ryu MH; Park SR; Choi WM; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY; Yoo C
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7547-7555. PubMed ID: 36971796
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma.
Kim EJ; Yoo C; Kang HJ; Kim KP; Ryu MH; Park SR; Lee D; Choi J; Shim JH; Kim KM; Lim YS; Lee HC; Ryoo BY
Liver Int; 2021 Jun; 41(6):1398-1408. PubMed ID: 33548073
[TBL] [Abstract][Full Text] [Related]
4. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
[TBL] [Abstract][Full Text] [Related]
5. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
6. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of patients with combined hepatocellular-cholangiocarcinoma after radical resection: A retrospective multicenter cohort study.
Zhang G; Chen BW; Yang XB; Wang HY; Yang X; Xie FC; Chen XQ; Yu LX; Shi J; Lu YY; Zhao HT
World J Gastroenterol; 2022 Nov; 28(41):5968-5981. PubMed ID: 36405111
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
9. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.
Lin CW; Wu TC; Lin HY; Hung CM; Hsieh PM; Yeh JH; Hsiao P; Huang YL; Li YC; Wang YC; Shu CW; Chen YS
BMC Gastroenterol; 2021 Jan; 21(1):20. PubMed ID: 33413162
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience.
Trikalinos NA; Zhou A; Doyle MBM; Fowler KJ; Morton A; Vachharajani N; Amin M; Keller JW; Chapman WC; Brunt EM; Tan BR
J Natl Compr Canc Netw; 2018 Oct; 16(10):1193-1199. PubMed ID: 30323089
[No Abstract] [Full Text] [Related]
12. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
14. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort.
Teufel A; Rodriguez I; Winzler C; Kokh D; Ebert MP; Surovtsova I; Morakis P
J Gastrointestin Liver Dis; 2023 Jun; 32(2):190-196. PubMed ID: 37345609
[TBL] [Abstract][Full Text] [Related]
16. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.
Gigante E; Hobeika C; Le Bail B; Paradis V; Tougeron D; Lequoy M; Bouattour M; Blanc JF; Ganne-Carrié N; Tran H; Hollande C; Allaire M; Amaddeo G; Regnault H; Vigneron P; Ronot M; Elkrief L; Verset G; Trepo E; Zaanan A; Ziol M; Ningarhari M; Calderaro J; Edeline J; Nault JC
Liver Cancer; 2022 Sep; 11(5):460-473. PubMed ID: 36158591
[TBL] [Abstract][Full Text] [Related]
17. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.
Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788
[TBL] [Abstract][Full Text] [Related]
18. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
19. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular-cholangiocarcinoma.
Gigante E; Ronot M; Bertin C; Ciolina M; Bouattour M; Dondero F; Cauchy F; Soubrane O; Vilgrain V; Paradis V
Liver Int; 2019 Dec; 39(12):2386-2396. PubMed ID: 31544304
[TBL] [Abstract][Full Text] [Related]
20. [Cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in cirrhotic patients].
Salinas M; Simian D; Carreño L; Cattaneo M; Urzúa Á; Sauré A; Lembach H; Castillo J; Díaz JC; Poniachik J
Rev Med Chil; 2022 Nov; 150(11):1431-1437. PubMed ID: 37358168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]